Abstract
AbstractA group of 54 exceptional responders (ERs) to cancer treatment across a variety of cancers and treatments were compared to typical cancer patients using previously defined polygenic risk scores (PRS) for multiple autoimmune-related diseases including type 1 diabetes (T1D), hypothyroidism, psoriasis, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel (IBD) disease. Most of the ERs were not treated with checkpoint inhibitors and included a broad array of tumor types. Significantly elevated PRSs were found between ERs relative to typical cancer patients in T1D, hypothyroidism, and psoriasis. IBD PRS scores were significantly decreased in the ERs.
Publisher
Cold Spring Harbor Laboratory
Reference29 articles.
1. Going to extremes: determinants of extraordinary response and survival in patients with cancer;Nat Rev Cancer [Internet],2019
2. Exceptional Response to Olaparib in a Patient With Recurrent Ovarian Cancer and an Entire BRCA1 Germline Gene Deletion;J Natl Compr Canc Netw [Internet],2020
3. Kingston B , Bailleux C , Delaloge S , Schiavon G , Scott V , Lacroix-Triki M , et al. Exceptional Response to AKT Inhibition in Patients With Breast Cancer and Germline PTEN Mutations. JCO Precis Oncol [Internet]. 2019;3. Available from: http://dx.doi.org/10.1200/PO.19.00130
4. Craig DW , O’Shaughnessy JA , Kiefer JA , Aldrich J , Sinari S , Moses TM , et al. Genome and transcriptome sequencing in prospective refractory metastatic triple negative breast cancer uncovers therapeutic vulnerabilities. Mol Cancer Ther [Internet]. Citeseer; 2012; Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=23171949&retmode=ref&cmd=prlinks
5. Abstract 2722: The genomic landscape of high-grade serous ovarian cancer in long-term survivors;Cancer Res [Internet]. American Association for Cancer Research,2019